Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The response accurately reflects FDA label language in Sections 5.1 and 4 regarding rodent thyroid C-cell tumors, the unknown human relevance (including MTC), and contraindications for personal/family history of MTC or MEN 2, with no direct contradictions identified.
Category Scores
Accurate Statements
Semaglutide causes dose- and treatment-duration-dependent thyroid C-cell tumors (adenomas and carcinomas) in mice and rats.
Section 5.1 (Risk of Thyroid C-Cell Tumors)
It is unknown whether OZEMPIC causes thyroid C-cell tumors, including MTC, in humans because human relevance has not been determined.
Section 5.1 (Risk of Thyroid C-Cell Tumors)
OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
Section 4 (Contraindications) and linked reference to 5.1
No safety contradiction was identified, and the label language is appropriately cautious regarding human MTC causality while contraindicating MTC/MEN 2 risk groups.
Sections 4 and 5.1 (collectively reflect contraindication and unknown human relevance wording)
Unsupported Statements
Contradictions
Important Omissions
The response does not mention the label’s routine monitoring statements (e.g., uncertain value of routine calcitonin/thyroid ultrasound) or patient counseling symptom examples from Sections 5.1 and 17.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The key safety-relevant elements for the requested topic (unknown human relevance of semaglutide-induced rodent C-cell tumors including MTC, and contraindications for MTC/MEN 2) are accurately represented.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission: the response does not include label details on monitoring uncertainty and/or specific patient counseling symptom examples.
Suggested Improvement
Add that routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value and include the label’s symptom counseling examples (e.g., neck mass, hoarseness, dysphagia, dyspnea) if addressing the boxed warning topic comprehensively.